Insider Transactions in Q1 2021 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
Jayne B. Hart Officer |
SELL
Open market or private sale
|
Direct |
58,000
-18.84%
|
$1,740,000
$30.0 P/Share
|
|
Mar 29
2021
|
Jayne B. Hart Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,000
+15.54%
|
$1,334,000
$23.08 P/Share
|
|
Mar 24
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,774
+8.79%
|
-
|
|
Mar 24
2021
|
Nicole Lambert Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,556
+17.88%
|
-
|
|
Mar 24
2021
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,441
+8.95%
|
-
|
|
Mar 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,347
+6.78%
|
-
|
|
Mar 24
2021
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,326
+19.29%
|
-
|
|
Mar 24
2021
|
Paul Parkinson EVP Strategy and Innovation |
BUY
Grant, award, or other acquisition
|
Direct |
10,661
+10.87%
|
-
|
|
Mar 24
2021
|
Benjamin Jackson E.V.P., General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
18,879
+14.99%
|
-
|
|
Mar 24
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,326
+14.26%
|
-
|
|
Mar 24
2021
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
159,915
+25.84%
|
-
|
|
Feb 18
2021
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+19.07%
|
-
|
|
Feb 18
2021
|
Margaret Ancona SVP, Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Feb 18
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,175
-3.51%
|
$324,075
$29.69 P/Share
|
|
Feb 16
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
80,000
-12.7%
|
$2,320,000
$29.71 P/Share
|
|
Feb 16
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+10.49%
|
$1,440,000
$18.0 P/Share
|
|
Jan 08
2021
|
Paul Parkinson EVP Strategy and Innovation |
SELL
Open market or private sale
|
Direct |
11,824
-13.35%
|
$295,600
$25.0 P/Share
|